Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to advance the company's Phase 1b clinical trials of ST-001 (nanofenretinide) for T-cell non-Hodgkin lymphoma and subsequent clinical trials for small cell lung cancer.
Lead Product(s): Fenretinide
Therapeutic Area: Oncology Product Name: ST-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Storm Lake Capital
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Financing June 04, 2024
Details:
SciTech's primary drug candidate, ST-001 (fenretinide), is currently undergoing Phase I clinical trials in IV infusion form for treating patients with T-cell non-Hodgkin's lymphoma, including Peripheral T-cell Lymphoma and Sezary Syndrome.
Lead Product(s): Fenretinide
Therapeutic Area: Oncology Product Name: ST-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
Fenretinide has demonstrated preclinical in-vitro antiviral activity against a number of viruses including MERs, Dengue, Zika, West Nile, HIV, and HCV.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020